Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429466 | 0.89 | KMT2A (0.38) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL4337709 | 0.87 | KMT2A (0.41) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL16074588 | 0.81 | POLB (0.44) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL24801766 | 0.79 | KMT2A (0.41) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL3431795 | 0.79 | SLC6A2 (0.38) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL8826885 | 0.75 | P2RX7 (0.38) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL1361091 | 0.75 | ALDH1A1 (0.48) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL19049562 | 0.74 | KMT2A (0.34) | KMT2AMEN1 | |
| SCHEMBL4027588 | 0.74 | PIK3CD (0.56) | PIK3CD | |
| SCHEMBL9848807 | 0.73 | PLA2G2A (0.44) | KMT2ASLC6A2SLC6A4SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | KMT2A 2028/4885SLC6A2 2629/4885SLC6A4 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.